Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules
Drug candidates derived from oligonucleotides (ON) are receiving increased attention that is supported by the clinical approval of several ON drugs. Such therapeutic ON are designed to alter the expression levels of specific disease-related proteins, e.g., by displaying antigene, antisense, and RNA...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/25/24/5963 |
id |
doaj-cfc9c0cde5b0490d8e719b847fa1870c |
---|---|
record_format |
Article |
spelling |
doaj-cfc9c0cde5b0490d8e719b847fa1870c2020-12-17T00:04:37ZengMDPI AGMolecules1420-30492020-12-01255963596310.3390/molecules25245963Cellular Targeting of Oligonucleotides by Conjugation with Small MoleculesManuel Hawner0Christian Ducho1Department of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2 3, 66 123 Saarbrücken, GermanyDepartment of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, Campus C2 3, 66 123 Saarbrücken, GermanyDrug candidates derived from oligonucleotides (ON) are receiving increased attention that is supported by the clinical approval of several ON drugs. Such therapeutic ON are designed to alter the expression levels of specific disease-related proteins, e.g., by displaying antigene, antisense, and RNA interference mechanisms. However, the high polarity of the polyanionic ON and their relatively rapid nuclease-mediated cleavage represent two major pharmacokinetic hurdles for their application in vivo. This has led to a range of non-natural modifications of ON structures that are routinely applied in the design of therapeutic ON. The polyanionic architecture of ON often hampers their penetration of target cells or tissues, and ON usually show no inherent specificity for certain cell types. These limitations can be overcome by conjugation of ON with molecular entities mediating cellular ‘targeting’, i.e., enhanced accumulation at and/or penetration of a specific cell type. In this context, the use of small molecules as targeting units appears particularly attractive and promising. This review provides an overview of advances in the emerging field of cellular targeting of ON via their conjugation with small-molecule targeting structures.https://www.mdpi.com/1420-3049/25/24/5963oligonucleotidesconjugationsmall moleculescellular targeting |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Manuel Hawner Christian Ducho |
spellingShingle |
Manuel Hawner Christian Ducho Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules Molecules oligonucleotides conjugation small molecules cellular targeting |
author_facet |
Manuel Hawner Christian Ducho |
author_sort |
Manuel Hawner |
title |
Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules |
title_short |
Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules |
title_full |
Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules |
title_fullStr |
Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules |
title_full_unstemmed |
Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules |
title_sort |
cellular targeting of oligonucleotides by conjugation with small molecules |
publisher |
MDPI AG |
series |
Molecules |
issn |
1420-3049 |
publishDate |
2020-12-01 |
description |
Drug candidates derived from oligonucleotides (ON) are receiving increased attention that is supported by the clinical approval of several ON drugs. Such therapeutic ON are designed to alter the expression levels of specific disease-related proteins, e.g., by displaying antigene, antisense, and RNA interference mechanisms. However, the high polarity of the polyanionic ON and their relatively rapid nuclease-mediated cleavage represent two major pharmacokinetic hurdles for their application in vivo. This has led to a range of non-natural modifications of ON structures that are routinely applied in the design of therapeutic ON. The polyanionic architecture of ON often hampers their penetration of target cells or tissues, and ON usually show no inherent specificity for certain cell types. These limitations can be overcome by conjugation of ON with molecular entities mediating cellular ‘targeting’, i.e., enhanced accumulation at and/or penetration of a specific cell type. In this context, the use of small molecules as targeting units appears particularly attractive and promising. This review provides an overview of advances in the emerging field of cellular targeting of ON via their conjugation with small-molecule targeting structures. |
topic |
oligonucleotides conjugation small molecules cellular targeting |
url |
https://www.mdpi.com/1420-3049/25/24/5963 |
work_keys_str_mv |
AT manuelhawner cellulartargetingofoligonucleotidesbyconjugationwithsmallmolecules AT christianducho cellulartargetingofoligonucleotidesbyconjugationwithsmallmolecules |
_version_ |
1724380723083739136 |